Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

Most comprehensive genome-wide experimental analyses of sense-antisense transcripts to date

A team of scientists led by Dr. Kuniya Abe from the RIKEN BioResource Center in Japan has performed one of the most comprehensive genome-wide experimental analyses of sense-antisense transcripts to date. Their findings are published in the April issue of the journal Genome Research.

15 Mar 2005

VIRxSYS novel HIV gene therapy yields exciting results

VIRxSYS Corporation reports unexpected and unprecedented findings in its ongoing Phase I clinical trial of its VRX496 therapy in patients with HIV.

28 Feb 2005

FDA approves Topigen's investigational New Drug Application for new inhalation drug to treat asthma

Phase 1 clinical trial can be initiated for ASM8, a new inhalation drug that is designed to treat asthma through a unique approach by attacking multiple mediators of the inflammatory mechanism rather than the single mediator approach of current therapies.

8 Dec 2004

Scientist develops way to deliver promising genetic tool into living cells

By exploiting an HIV protein that readily traverses cell membranes, Carnegie Mellon University scientists have developed a new way to introduce a gene-like molecule called a peptide nucleic acid (PNA) directly into live mammalian cells, including human embryonic stem (ES) cells.

6 Dec 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.

20 Sep 2004

Researchers using light to control genes and better understand the role of certain genes in embryonic development

As our understanding of biology increases, the tools of research become almost as important as the researchers wielding them. Currently, one of the major obstacles to research is actually getting inside of cells and tissue to see what is going on as it happens.

25 Aug 2004

Scientists have turned procrastinating primates into workaholics by temporarily suppressing a gene in a brain circuit involved in reward learning

Using a new molecular genetic technique, scientists have turned procrastinating primates into workaholics by temporarily suppressing a gene in a brain circuit involved in reward learning. Without the gene, the monkeys lost their sense of balance between reward and the work required to get it, say researchers at the National Institute of Mental Health .

11 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

DNA left overs, new mechanism for evolution

A team of researchers from the Universitat Autònoma de Barcelona (UAB) has discovered that transposons, small DNA sequences that travel through the genomes, can silence the genes adjacent to them by inducing a molecule called antisense RNA.

16 Jul 2004

3 people with drug-resistant HIV become first to undergo a new form of gene therapy

The idea is to use a modified form of HIV to deliver an "antisense" gene to the immune cells that HIV infects. This is integrated into the cells' genome, and stays there until a cell is infected. Then it is switched on, and produces RNA complementary to the "sense" RNA encoding a viral protein. In theory, the RNAs should bind together, blocking viral replication.

14 May 2004

Treatment for ovarian cancer by gene targeting

Targeting and inactivating a key gene could be a subtle and effective treatment for certain types of ovarian cancer, Scottish researchers suggest in a study published in Clinical Cancer Research.

22 Mar 2004